Acologix is a biology-based biopharmaceutical company focusing on the identification and development of novel therapeutics for major unmet medical needs. The Company name Acologix comes from the Greek word, acology, which means the science of remedies. The Company has six product candidates in its pipeline. Its lead compound, Dentonin (AC-100), completed a Phase I clinical trial in 2003 and is expected to enter a phase IIa study later in 2004. Acologix is now focused on the development of several additional product candidates which are planned to enter clinical trials in 2005. The current product candidates target the treatment of bone, teeth, kidney, vascular system and inflammatory diseases as well as metastatic cancer.